GH Research PLC GHRS 深 沪
已收盘 09-12 16:00:00 美东时间
11.94
-0.540
-4.33%
华盛通- 最 高12.47
- 今 开12.44
- 成交量 16.41万股
- 最 低 11.83
- 昨 收 12.48
- 总市值 7.41亿
- 52周最高 20.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.00
- 委 比 34.54%
- 总股本 6202.94万
- 历史最高 30.43
- 量 比 0.88
- 振 幅 5.13%
- 历史最低 5.05
- 每 手 1
- 风险率 2.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Shares of psychedelic companies are trading higher after a GOP senator stated he's "confident" that under the Trump administration, lawmakers will help secure alternative treatment options for military veterans, including access to psychedelic medicine.
Shares of psychedelic companies are trading higher after a GOP senator stated h...
08-26 02:53
GH Research GAAP EPS of -$0.15
GH Research press release (NASDAQ:GHRS): Q2 GAAP EPS of -$0.15. Cash, cash equivalents, short- and long-term investments, and interest receivable were $510.9 million as of June 30, 2025. More on GH...
08-07 21:34
GH Research Q2 EPS $(0.15) Beats $(0.21) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.21) by 30.23 percent. This is a 25 percent increase over losses of $(0.20) per share from the same
08-07 19:15
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
GH Research PLC reported financial results for Q2 2025, including $308.7M in cash, and provided updates on its pivotal program for 2026. The GH001 clinical trial met its primary endpoint with a 73% remission rate at 6 months, showing favorable safety and tolerability. The company also announced progress on GH002 and ongoing FDA engagement for IND responses.
08-07 11:00
GH Research Announces Global Pivotal Program Plans and Further Development Updates
GH Research PLC has provided updates on its business and upcoming milestones. Engagement with the FDA on the complete response to the IND for GH001 is ongoing, with only one hold topic remaining. Phase 2b TRD trial results show a 73% remission rate at 6 months with no serious adverse events. GH002 Phase 1 results demonstrate safety and rapid effects, with an IND expected in Q4 2025. The global pivotal program is on track to commence in 2026.
07-23 12:00
Shares of psychedelic companies are trading higher following a report suggesting California Governor Newsom said he is "all in" on expanding access to psychedelics for therapeutic use.
Shares of psychedelic companies are trading higher following a report suggestin...
07-22 00:31
'House Votes To Let VA Doctors Recommend Medical Marijuana To Military Veterans And To Support Psychedelics Research'
https://www.marijuanamoment.net/house-votes-to-let-va-doctors-recommend-medical-marijuana-to-military-veterans-and-to-support-psychedelics-research/
06-26 01:42
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Psychedelic medicine stocks fall following Compass depression asset data
Most companies operating in the psychedelic medicine space are down significantly after Compass Pathways (NASDAQ:CMPS) on Monday posted late-stage data on its psilocybin-based treatment for treatment-...
06-24 03:24
